Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01CA069855-02
Application #
2113830
Study Section
Special Emphasis Panel (NSS)
Project Start
1995-05-15
Project End
1998-02-28
Budget Start
1996-02-29
Budget End
1997-02-28
Support Year
2
Fiscal Year
1996
Total Cost
Indirect Cost
Name
University of Pittsburgh
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
053785812
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Aregbe, Abdulateef O; Sherer, Eric A; Egorin, Merrill J et al. (2012) Population pharmacokinetic analysis of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in adult patients with solid tumors. Cancer Chemother Pharmacol 70:201-5
Leal, Ticiana B; Remick, Scot C; Takimoto, Chris H et al. (2011) Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study. Cancer Chemother Pharmacol 68:1439-47
Ramanathan, Ramesh K; Egorin, Merrill J; Erlichman, Charles et al. (2010) Phase I pharmacokinetic and pharmacodynamic study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an inhibitor of heat-shock protein 90, in patients with advanced solid tumors. J Clin Oncol 28:1520-6
Ramanathan, Ramesh K; Egorin, Merrill J; Takimoto, Chris H M et al. (2008) Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of liver dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group. J Clin Oncol 26:563-9
Ramanathan, Ramesh K; Egorin, Merrill J; Eiseman, Julie L et al. (2007) Phase I and pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with refractory advanced cancers. Clin Cancer Res 13:1769-74
Synold, Timothy W; Takimoto, Chris H; Doroshow, James H et al. (2007) Dose-escalating and pharmacologic study of oxaliplatin in adult cancer patients with impaired hepatic function: a National Cancer Institute Organ Dysfunction Working Group study. Clin Cancer Res 13:3660-6
Eiseman, Julie L; Guo, Jianxia; Ramanathan, Ramesh K et al. (2007) Evaluation of plasma insulin-like growth factor binding protein 2 and Her-2 extracellular domain as biomarkers for 17-allylamino-17-demethoxygeldanamycin treatment of adult patients with advanced solid tumors. Clin Cancer Res 13:2121-7
Takimoto, Chris H; Graham, Martin A; Lockwood, Graham et al. (2007) Oxaliplatin pharmacokinetics and pharmacodynamics in adult cancer patients with impaired renal function. Clin Cancer Res 13:4832-9
Ramanathan, Ramesh K; Fakih, Marwan; Mani, Sridhar et al. (2006) Phase I and pharmacokinetic study of the novel redox-active agent, motexafin gadolinium, with concurrent radiation therapy in patients with locally advanced pancreatic or biliary cancers. Cancer Chemother Pharmacol 57:465-74
Chen, Xueyu; Bies, Robert R; Ramanathan, Ramesh K et al. (2005) Population pharmacokinetic analysis of 17-(allylamino)-17-demethoxygeldanamycin (17AAG) in adult patients with advanced malignancies. Cancer Chemother Pharmacol 55:237-43

Showing the most recent 10 out of 20 publications